Premium
Molecular remodelling of human CD46 for xenotransplantation: designing a potent complement regulator without measles virus receptor activity
Author(s) -
Begum N. A.,
Murakami Y.,
Mikata S.,
Matsumoto M.,
Hatanaka M.,
Nagasawa S.,
Kinoshita T.,
Seya T.
Publication year - 2000
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1046/j.1365-2567.2000.00999.x
Subject(s) - cd46 , xenotransplantation , measles virus , biology , decay accelerating factor , cd59 , immune system , complement system , immunology , receptor , complement control protein , virus , virology , microbiology and biotechnology , transplantation , measles , medicine , genetics , vaccination , surgery
Summary In pig‐to‐human discordant xenotransplantation, human complement (C) is a major barrier to long survival of xenografts. The current idea on how to cope with this barrier is that human complement regulatory proteins are forcibly expressed on xenografts to serve as safeguards against host C‐induced hyperacute rejection of xenografts. Co‐expression of decay‐accelerating factor (DAF) (CD55) and membrane cofactor protein (MCP) (CD46) would be the first choice for this trial, because most of the human cells are protected from C‐mediated damage by two different modes with these two kinds of C‐regulators. Many problems have arisen, however, for MCP expression on grafts. (i) MCP acts as a measles virus receptor, which may function to render donor pigs measles virus (MV) sensitive. (ii) MCP signals immune suppression which causes devastation of the recipient's immune responses. (iii) MCP exerts relatively low self‐protective activity against C compared with other cofactors; development of more efficient forms is desirable. (iv) Grafts with a high expression level of MCP are difficult to produce. In this study, we made a number of cDNA constructs of MCP, expressed them on swine endothelial cell lines, and tested cell‐protective potency and MV susceptibility. The short consensus repeat 1 (SCR1)‐deleted MCP with glycosyl phosphatidylinositol (GPI)‐anchored form (Δ1MCP‐PI) of MCP was found to be most suitable for the purpose of overcoming these problems. However, it was also found that MV induces two modes of cytopathic effect (CPE) on swine endothelial cells, either MCP‐dependent or ‐independent. Here, we discuss these two points which will be raised through study of MCP‐transgenic animals.